Long-term Survival in Glioblastoma with Cytomegalovirus pp65-Targeted Vaccination
نویسندگان
چکیده
منابع مشابه
Long-term Survival in Glioblastoma with Cytomegalovirus pp65-Targeted Vaccination.
Purpose: Patients with glioblastoma have less than 15-month median survival despite surgical resection, high-dose radiation, and chemotherapy with temozolomide. We previously demonstrated that targeting cytomegalovirus pp65 using dendritic cells (DC) can extend survival and, in a separate study, that dose-intensified temozolomide (DI-TMZ) and adjuvant granulocyte macrophage colony-stimulating f...
متن کاملGlioblastoma multiforme with long term survival.
Glioblastoma multiforme (GBM) Patients generally have a dismal prognosis, with median survival of 10-12 months. GBM with long-term survival (LTS) of (3) > or = 5 years is rare, and no definite markers indicating better prognosis have been identified till date. The present study was undertaken to evaluate GBMs with LTS in order to identify additional correlates associated with favourable outcome...
متن کاملLong-term survival with glioblastoma multiforme.
The median survival of glioblastoma patients is approximately 12 months. However, 3-5% of the patients survives for more than 3 years and are referred to as long-term survivors. The clinical and molecular factors that contribute to long-term survival are still unknown. To identify specific parameters that might be associated with this phenomenon, we performed a detailed clinical and molecular a...
متن کاملLong-term survival of a patient with glioblastoma.
gliomas and has a median survival of 13.6 months even with aggressive surgical resection, radiation and chemotherapy1. This dismal prognosis is compounded by the failure of novel therapies to yield more than minimal prognostic improvements. A major advance was adjuvant temozolamide treatment but this increased median survival in multi-centre trials by only 2.5 months2-4. Prognostic indicators h...
متن کاملLong-term survival with unmethylated MGMT glioblastoma multiforme
Introduction: Glioblastoma multiforme is the most aggressive tumor of the central nervous system. Despite advances in its management, overall prognosis remains poor, with a median survival time of less than one year. Good response to chemotherapy with temozolomide (TMZ) is usually associated with methylation of the promoter of the O(6)-methylguanine-DNA methyltransferase (MGMT) gene. Case Repor...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Clinical Cancer Research
سال: 2017
ISSN: 1078-0432,1557-3265
DOI: 10.1158/1078-0432.ccr-16-2057